The Gut Microbiome and Pediatric Cancer: Current Research and Gaps in Knowledge

J Natl Cancer Inst Monogr. 2019 Sep 1;2019(54):169-173. doi: 10.1093/jncimonographs/lgz026.

Abstract

The human microbiome consists of trillions of microbial cells that interact with one another and the human host to play a clinically significant role in health and disease. Gut microbial changes have been identified in cancer pathogenesis, at disease diagnosis, during therapy, and even long after completion of treatment. Alterations in the gut microbiome have been linked to treatment-related toxicity and potential long-term morbidity and mortality in children with cancer. Such alterations are plausible given immune modulation due to disease as well as exposure to cytotoxic chemotherapy, infections, and antibiotics. The following review presents our current scientific understanding on the role of the gut microbiome in pediatric cancer, identifies gaps in knowledge, and suggests future research goals.

Publication types

  • Review

MeSH terms

  • Age Factors
  • Anti-Infective Agents / adverse effects
  • Anti-Infective Agents / therapeutic use
  • Child
  • Comorbidity
  • Disease Susceptibility*
  • Dysbiosis
  • Gastrointestinal Microbiome* / drug effects
  • Gastrointestinal Microbiome* / immunology
  • Humans
  • Immunomodulation
  • Microbiota
  • Neoplasms / diagnosis
  • Neoplasms / epidemiology*
  • Neoplasms / etiology*
  • Neoplasms / therapy
  • Prognosis

Substances

  • Anti-Infective Agents